ALK rearrangement in non-small cell lung cancer

被引：0

作者：

Naulleau, Gaspard ^{[1
]}

Birsen, Gary ^{[1
]}

Mansuet-Lupo, Audrey ^{[2
,3
]}

Leroy, Karen ^{[4
]}

Wislez, Marie ^{[1
,3
]}

机构：

[1] Univ Paris Cite, Hop Cochin, AP HP Ctr, Serv Pneumol, Paris, France

[2] Univ Paris Cite, Hop Cochin, AP HP Ctr, Serv Anat Pathol, Paris, France

[3] Univ Paris Cite, Ctr Rech Cordeliers, Equipe Inflammat Complement & Canc, INSERM,U1138, Paris, France

[4] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Serv Biochim, Paris, France

来源：

BULLETIN DU CANCER | 2025年 / 112卷 / 03期

关键词：

ALK rearrangement; Targeted therapy; Non-small cell lung carcinoma; Resistance mechanisms; GENERATION SEQUENCING REVEALS; RECEPTOR TYROSINE KINASE; EML4-ALK FUSION GENE; HISTOLOGICAL TRANSFORMATION; NSCLC PATIENTS; RESISTANCE; ADENOCARCINOMA; CRIZOTINIB; MUTATION; ALECTINIB;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery of ALK gene rearrangement in 3 to 5% of non-small cell lung carcinomas has revolutionized our understanding and therapeutic approach of these cancers. This oncogenic driver is associated with specific clinical and biological features is associated with specific clinical and biological features, mainly affecting young and never-smoker patients, with a particular tropism outcomes, with remarkable efficacy of latest-generation molecules, particularly in controlling brain metastases. However, the emergence of complex resistance mechanisms, whether ALK-dependent or ALK-independent, remains a major challenge. The comprehensive understanding of these resistance mechanisms now guides the development of next-generation inhibitors and innovative therapeutic strategies, paving the way for increasingly personalized precision medicine.

引用

页码：3S86 / 3S94

页数：9

共 68 条

[1] Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient [J].

Ai, Xinghao ;

Niu, Xiaomin ;

Chang, Lianpeng ;

Chen, Rongrong ;

Ou, Sai-Hong Ignatius ;

Lu, Shun .

LUNG CANCER, 2018, 123 :83-86

[2]

Ambrosini P, 2025, CLIN LUNG CANCER, V26, pe11, DOI [10.1016/j.cllc.2024.11.012, 10.1016/j.clc.2024.11.012]

[3] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

[4] A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib [J].

Cha, Yoon Jin ;

Cho, Byoung Chul ;

Kim, Hye Ryun ;

Lee, Hye-Jeong ;

Shim, Hyo Sup .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) :E55-E58

[5] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].

Choi, Young Lim ;

Soda, Manabu ;

Yamashita, Yoshihiro ;

Ueno, Toshihide ;

Takashima, Junpei ;

Nakajima, Takahiro ;

Yatabe, Yasushi ;

Takeuchi, Kengo ;

Hamada, Toru ;

Haruta, Hidenori ;

Ishikawa, Yuichi ;

Kimura, Hideki ;

Mitsudomi, Tetsuya ;

Tanio, Yoshiro ;

Mano, Hiroyuki .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739

[6] Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib [J].

Coleman, Niamh ;

Wotherspoon, Andrew ;

Yousaf, Nadia ;

Popat, Sanjay .

LUNG CANCER, 2019, 134 :117-120

[7] Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review [J].

Desai, Aakash ;

Lovly, Christine M. .

TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) :615-628

[8] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[9] NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations [J].

Drilon, Alexander ;

Horan, Joshua C. ;

Tangpeerachaikul, Anupong ;

Besse, Benjamin ;

Ou, Sai-Hong Ignatius ;

Gadgeel, Shirish M. ;

Camidge, D. Ross ;

Wekken, Anthonie J. van der ;

Nguyen-Phuong, Linh ;

Acker, Adam ;

Keddy, Clare ;

Nicholson, Katelyn S. ;

Yoda, Satoshi ;

Mente, Scot ;

Sun, Yuting ;

Soglia, John R. ;

Kohl, Nancy E. ;

Porter, James R. ;

Shair, Matthew D. ;

Zhu, Viola ;

Davare, Monika A. ;

Hata, Aaron N. ;

Pelish, Henry E. ;

Lin, Jessica J. .

CANCER DISCOVERY, 2023, 13 (03) :598-615

[10] Prospective screening for ALK: Clinical features and outcome according to ALK status [J].

Fallet, Vincent ;

Cadranel, Jacques ;

Doubre, Helene ;

Toper, Cecile ;

Monnet, Isabelle ;

Chinet, Thierry ;

Oliviero, Gerard ;

Foulon, Guillaume ;

De Cremoux, Hubert ;

Vieira, Thibault ;

Antoine, Martine ;

Wislez, Marie .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) :1239-1246

← 1 2 3 4 5 6 7 →